<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461406</url>
  </required_header>
  <id_info>
    <org_study_id>IG1405</org_study_id>
    <nct_id>NCT03461406</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects</brief_title>
  <official_title>A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, active-controlled, single-blind, parallel group clinical&#xD;
      trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during&#xD;
      surgery in pediatric subjects.&#xD;
&#xD;
      Pediatric subjects (&lt;18 years of age) requiring an elective (non-emergent), open&#xD;
      (non-laparoscopic), pelvic, abdominal, or thoracic (non-cardiac) surgical procedure, wherein&#xD;
      a target bleeding site (TBS) is identified, and a topical hemostatic agent is indicated, will&#xD;
      be eligible to participate in the clinical trial.&#xD;
&#xD;
      The study treatments will be applied on the cut parenchymous surface of a solid organ (ie,&#xD;
      liver) and in soft tissue (ie, fat, muscle, or connective tissue).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, active-controlled, single-blind, parallel group clinical&#xD;
      trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during&#xD;
      surgery. Approximately 172 pediatric subjects will be enrolled and will be randomly allocated&#xD;
      in a 1:1 ratio into 1 of 2 treatment groups: FS Grifols or EVICEL. Enrollment will be&#xD;
      monitored by surgery type to ensure at least 50% of the surgical procedures are hepatic.&#xD;
&#xD;
      A specific bleeding site will be defined as the TBS when it is determined by the investigator&#xD;
      (the surgeon) that control of bleeding by conventional surgical techniques (including suture,&#xD;
      ligature, and cautery) is ineffective or impractical and requires an adjunct treatment to&#xD;
      achieve hemostasis.&#xD;
&#xD;
      When the TBS is identified, the investigator will record the precise anatomical location of&#xD;
      the TBS, rate the intensity of the bleeding at the TBS (Grade 1-4 according to a 5-point&#xD;
      validated bleeding severity scale), and record the size of the approximate bleeding surface,&#xD;
      (small, medium, and large). For soft tissue surgery only, the investigator will also record&#xD;
      the type of soft tissue (ie, fat, muscle, or connective tissue). In this clinical trial, only&#xD;
      subjects with a TBS with bleeding of Grade 1 (mild) or Grade 2 (moderate) intensity will be&#xD;
      enrolled.&#xD;
&#xD;
      This study includes a Screening Visit to determine subject eligibility, a Baseline Visit, the&#xD;
      Surgical Procedure (Day 1), and Post-operative assessments at Days 1, 4, and 30. The total&#xD;
      duration of a subject's participation in this study is expected to be no longer than 2 months&#xD;
      from the Screening Visit to the Post-operative Day 30 Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Hemostasis Within 4 Minutes After Treatment Start (T4)</measure>
    <time_frame>From start of treatment until 4 minutes after treatment start</time_frame>
    <description>Subjects achieving hemostasis at the target bleeding site within 4 minutes following the start of treatment without the occurrence of re-bleeding or reapplication of study treatment after T4 and until the completion of surgical closure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Proportion of Subjects Achieving Hemostasis at the Target Bleeding Site by 7 Minutes After Treatment Start (T7).</measure>
    <time_frame>From start of treatment to 7 minutes after start of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Proportion of Subjects Achieving Hemostasis at the Target Bleeding Site by 10 Minutes After Treatment Start (T10).</measure>
    <time_frame>From start of treatment to 10 minutes after start of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Treatment Failures</measure>
    <time_frame>From start of treatment up to 10 minutes after start of treatment and until the time of completion of surgical closure.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Excessive Bleeding During Surgery</condition>
  <arm_group>
    <arm_group_label>Fibrin Sealant Grifols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVICEL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>human fibrinogen (55-85 mg/mL) and human thrombin (800-1200 IU/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibrin Sealant Grifols</intervention_name>
    <description>human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution) solutions filled in syringes and assembled on a syringe holder</description>
    <arm_group_label>Fibrin Sealant Grifols</arm_group_label>
    <other_name>FS Grifols</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EVICEL</intervention_name>
    <description>1 vial of Biological Active Component 2, a frozen, sterile solution consisting of a concentrate of human fibrinogen (55-85 mg/mL) and 1 vial of thrombin (800-1200 IU/mL)</description>
    <arm_group_label>EVICEL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pre-operative:&#xD;
&#xD;
          1. Less than 18 years of age.&#xD;
&#xD;
          2. Requires an elective (non-emergent), open (non-laparoscopic), pelvic, abdominal, or&#xD;
             thoracic (non-cardiac) surgical procedure.&#xD;
&#xD;
          3. Subject and/or subject's legal guardian is willing to give permission for the subject&#xD;
             to participate in the clinical trial and provide written informed consent for the&#xD;
             subject. In addition, assent must be obtained from pediatric subjects who possess the&#xD;
             intellectual and emotional ability to comprehend the concepts involved in the clinical&#xD;
             trial.&#xD;
&#xD;
             Intra-operative:&#xD;
&#xD;
          4. Presence of an appropriate (as defined in inclusion criterion 5) parenchymous or soft&#xD;
             tissue TBS identified intra-operatively by the investigator (the surgeon).&#xD;
&#xD;
          5. TBS has Grade 1 (mild) or Grade 2 (moderate) bleeding intensity according to the&#xD;
             investigator's (the surgeon's) judgment. The intensity of the bleeding at the TBS will&#xD;
             be rated by the investigator using the 5-point validated bleeding severity scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pre-operative:&#xD;
&#xD;
          1. Admitted for trauma surgery.&#xD;
&#xD;
          2. Unwilling to receive blood products.&#xD;
&#xD;
          3. Known history of severe (eg, anaphylactic) reaction to blood products.&#xD;
&#xD;
          4. Known history of intolerance to any of the components of the investigational product&#xD;
             (IP).&#xD;
&#xD;
          5. Female subjects who are pregnant, breastfeeding or, if of child-bearing potential (ie,&#xD;
             adolescent), unwilling to practice a highly effective method of contraception.&#xD;
&#xD;
          6. Previously enrolled in a clinical trial with FS Grifols.&#xD;
&#xD;
          7. Currently participating, or during the study is planned to participate, in any other&#xD;
             investigational device or medicinal product study without prior and explicit approval&#xD;
             from the sponsor.&#xD;
&#xD;
             Intra-operative:&#xD;
&#xD;
          8. An appropriate parenchymous or soft tissue TBS (as defined in exclusion criteria 9 and&#xD;
             10) cannot be identified intra-operatively by the investigator (the surgeon).&#xD;
&#xD;
          9. TBS has Grade 3 (severe) bleeding according to the investigator's (the surgeon's)&#xD;
             judgment that cannot be controlled with conventional surgical techniques to Grade 1 or&#xD;
             Grade 2 bleeding. The intensity of the bleeding at the TBS will be rated by the&#xD;
             investigator using the 5-point validated bleeding severity scale.&#xD;
&#xD;
         10. TBS is in an actively infected surgical field.&#xD;
&#xD;
         11. Occurrence of major intra-operative complications that require resuscitation or&#xD;
             deviation from the planned surgical procedure.&#xD;
&#xD;
         12. Application of any topical hemostatic agent on the resection surface of parenchyma or&#xD;
             soft tissue prior to application of the IP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jordi Navarro Puerto</last_name>
    <phone>+34 93 571 2200</phone>
    <email>Jordi.Navarro@grifols.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lurie Childrens Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Michigan Center</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Urological Institute of Northeastern New York</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tomoaki Kato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Christophers Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MUSC Health-Children's Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dev Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Paso Childrens Hospital</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Carilion Children's Pediatric Surgery</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MHAT City clinic - Sveti Georgi</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveti Georgi</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UMHATEM N.I.Pirogov</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Prof. Dr. Stoyan Kirkovich</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Krasimira Kalinova, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia's Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <zip>4480</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Pédiatriques de Nice CHU-Lenval</name>
      <address>
        <city>Nice</city>
        <zip>6200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabine Irtan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, 2nd Dpt of Paediatrics</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zoltan Jenovari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heim Pál Pediatric Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>H-1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Clinical Center, Pediatric Clinic No. I.</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Petz Aladár County Teaching Hospital, Department of Pediatric Surgery</name>
      <address>
        <city>Győr</city>
        <zip>H-9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Pécs Clinical Centre, Pediatric Clinic</name>
      <address>
        <city>Pécs</city>
        <zip>H-7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Maria Sklodowska Curie&quot;</name>
      <address>
        <city>Bucarest</city>
        <zip>041434</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Grigore Alexandrescu&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>010623</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Balanescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400370</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Sfanta Maria&quot;</name>
      <address>
        <city>Iasi</city>
        <zip>700309</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Louis Turcanu&quot;</name>
      <address>
        <city>Timişoara</city>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Children' s Hospital</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleksandar Sretenović, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Healthcare Institute of Serbia &quot;Dr Vukan Cupic&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maja Milickovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis, Clinic for Pediatric Surgery and Orthopedics</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andjelka Slavkovic, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insititute for Health Protection of Children and Youth</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ericzon Bo-Goran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B46NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Khalid Sharif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clesea &amp; Westmisnter Hospital</name>
      <address>
        <city>London</city>
        <zip>SW109NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Southampton Children's Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO166YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

